A phase 2 clinical trial found that azelastine nasal spray could potentially prevent COVID-19 infections in healthy adults, as published in JAMA Internal Medicine. Among 450 study participants, SARS-CoV-2 infection as determined by polymerase chain reaction testing occurred in 2.2% of those using azelastine compared with 6.7% in the placebo group, representing a 67% relative risk reduction (odds ratio, 0.31; 95% confidence interval, 0.11-0.87). Symptomatic COVID-19 infections were also less frequent with azelastine (1.8% vs …
Read More